BriefingWire.com, 8/21/2011 - Immune Response BioPharma, Inc. -- Immune Response BioPharma, Inc. Reports NeuroVax MS Vaccine Increased Results with Women Taking Estrogen, a T Cell Receptor Vaccination is a Novel Approach to Treating MS.
Immune Response BioPharma, Inc., Fredericksburg, Virginia Today 8/21/2011 Immune Response BioPharma, Inc. Reports Increased Results of NeuroVax MS Vaccine with Women Taking Estrogen. T Cell Receptor Vaccination is a Novel Approach to Treating MS.
NeuroVax has shown increased results and effectiveness of the MS vaccine with women taking estrogen according to our friends at OHSU and Dr. Arthur Vandenbark. Both Dr. Arthur Vandenbark and clinician Dr. Bourdette great men of medicine and science have spent their careers developing highly targeted vaccines using TCR peptides such as NeuroVax. The vaccine is easy to manufacture, tolerable, shows clinical benefits, and is very safe from the data collected which can benefit the millions of MS patients who suffer from this debilitating disease.
“NeuroVax is a novel treatment option that has the opportunity to become the gold standard of care for patients suffering with MS. Our friends at Oregon Health & Science University Dr. Vandenbark and Dr. Bourdette are experts in this field and have developed a world class treatment for MS. It is a shame funding has held this important drug off of the market” COO Mr. Buswell of IRBP.
“I aim to change this for MS patients whose loved ones have been contacting me wanting this safe and therapeutic option and an affordable cost. I am going to make every effort to get the funding needed for this fantastic treatment option. We will hold a joint conference call in the coming future with our friends at OHSU and invite biotech investors and investment bankers to join our call to discuss NeuroVax and the opportunity along with plans for a phase 2 dose ranging trial, the date and time will be announced in the future” Mr. Buswell COO IRBP.
Forward-Looking Statement
Some of the statements made in this press release are forward looking in nature. These statements are based on management’s current expectations or beliefs. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Immune Response BioPharma, Inc.’s control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent Immune Response BioPharma, Inc. from achieving its stated goals include, but are not limited to: the current uncertainty in the global financial markets and the global economy. Including but not limited to the uncertainties regarding the approval of biopharmaceutical products in a highly regulated market.
Immune Response BioPharma may be found on the world wide web at www.immuneresponsebiopharma.com
Media Contact Info Info@immuneresponsebiopharma.com
Eric Swanson President of Investor Relations and Media Ericswanson@immuneresponsebiopharma.com
